drugset
drugset / Trial / NCT00557401

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

NCT00557401 ↗

Phase 2 Completed 156 enrolled XenoPort, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD

Timeline

Start
2007-11
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Arbaclofen Placarbil Small molecule 20 mg Oral
Subject Arbaclofen Placarbil Small molecule 30 mg Oral
Subject Arbaclofen Placarbil Small molecule 40 mg Oral
Subject Arbaclofen Placarbil Small molecule 60 mg Oral

Indications

gastroesophageal reflux disease